Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | GAA | P10253 | 4/20 | 0.59 |
| ▸ | METAP2 | P50579 | 2/20 | 0.58 |
| ▸ | METAP1 | P53582 | 1/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.57 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.57 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3984259 | 0.83 | METAP2 (0.76) | MEN1KMT2AGAAMETAP2METAP1 | |
| SCHEMBL3981226 | 0.83 | ACLY (0.60) | MEN1KMT2AGAAMETAP2METAP1 | |
| SCHEMBL3985999 | 0.77 | METAP2 (0.74) | MEN1KMT2AMETAP2METAP1ALDH1A1 | |
| SCHEMBL4277652 | 0.77 | METAP2 (0.69) | MEN1KMT2AGAAMETAP2METAP1 | |
| SCHEMBL17599381 | 0.76 | MEN1 (0.54) | MEN1KMT2AGAAPKMKDM4E | |
| SCHEMBL3987927 | 0.76 | METAP2 (0.58) | MEN1KMT2AGAAMETAP2METAP1 | |
| SCHEMBL3982436 | 0.76 | METAP2 (0.61) | MEN1KMT2AMETAP2METAP1KDM4E | |
| SCHEMBL3982685 | 0.76 | METAP2 (0.67) | MEN1KMT2AGAAMETAP2METAP1 | |
| SCHEMBL17599302 | 0.75 | FABP4 (0.61) | MEN1KMT2AGAAPKMKDM4E | |
| SCHEMBL3986500 | 0.74 | METAP2 (1.00) | MEN1KMT2AGAAMETAP2METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040068012-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-04-08 | — | — | US | claimed |
| US-7491718-B2 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES (US) | 2009-02-17 | — | — | US | disclosed |
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-08-12 | — | — | US | disclosed |
| US-20040068012-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | MEN1 580/4885KMT2A 647/4885GAA 1250/4885 |
| US-20040068012-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | MEN1 580/4885KMT2A 647/4885GAA 1250/4885 |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | MEN1 580/4885KMT2A 647/4885GAA 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.